Correction to: Combined gene expression and proteomic analysis of EGF induced apoptosis in A431 cells suggests multiple pathways trigger apoptosis (Apoptosis, (2013), 18, 11, (1291-1305), 10.1007/s10495-013-0887-6);Combined gene expression and proteomic analysis of EGF induced apoptosis in A431 cells suggests multiple pathways trigger apoptosis

Apoptosis

Volumn 18, Issue 11, 2013, Pages 1291-1305

  Alanazi, Ibrahim ^a   Ebrahimie, Esmaeil ^a   Hoffmann, Peter ^a   Adelson, David L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Apoptosis; Cancer; Cytoskeleton; EGF; Interferon

Indexed keywords

CELL PROTEIN; CYTOCHROME C; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERFERON; PROTEIN P53; SERPINB1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN A431; CONTROLLED STUDY; DOWN REGULATION; ENZYME RELEASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CYTOCHROMES C; CYTOSKELETON; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERPINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886389494     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-017-1431-x     Document Type: Erratum

References (61)

1. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167
2. Normanno N, Bianco C, Strizzi L et al (2005) The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6:243-257
3. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G (1998) Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 425:145-150
4. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
5. Rodeck U, Jost M, Kari C et al (1997) EGF-R dependent regulation of keratinocyte survival. J Cell Sci 110(Pt 2):113-121
6. Kari C, Chan TO, Rocha De Quadros M, Rodeck U (2003) Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63:1-5
7. Schneeweiss A, Kolay S, Aulmann S et al (2004) Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). Anticancer Drugs 15:235-238
8. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970
9. Janmaat ML, Giaccone G (2003) The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc) 39(Suppl C):61-80
10. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C (2003) EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol 55:713-723
11. Schmidt M, Lichtner RB (2002) EGF receptor targeting in therapy-resistant human tumors. Drug Resist Updat 5:11-18
12. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250
13. Gill GN, Lazar CS (1981) Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature 293:305-307
14. Barnes DW (1982) Epidermal growth-factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell-culture. J Cell Biol 93:1-4
15. Gill GN, Buss JE, Lazar CS, Lifshitz A, Cooper JA (1982) Role of epidermal growth factor-stimulated protein kinase in control of proliferation of A431 cells. J Cell Biochem 19:249-257
16. Gulli LF, Palmer KC, Chen YQ, Reddy KB (1996) Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 7:173-178
17. Weinstein EJ, Grimm S, Leder P (1998) The oncogene heregulin induces apoptosis in breast epithelial cells and tumors. Oncogene 17:2107-2113
18. Armstrong DK, Kaufmann SH, Ottaviano YL et al (1994) Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 54:5280-5283
19. Pinkas-Kramarski R, Alroy I, Yarden Y (1997) ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J Mammary Gland Biol Neoplasia 2:97-107
20. Bromberg JF, Fan Z, Brown C, Mendelsohn J, Darnell JE Jr (1998) Epidermal growth factor-induced growth inhibition requires Stat1 activation. Cell Growth Differ 9:505-512
21. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY (1997) Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 17:5328-5337
22. Watanabe G, Kaganoi J, Imamura M et al (2001) Progression of esophageal carcinoma by loss of EGF-STAT1 pathway. Cancer J 7:132-139
23. Ichiba M, Miyazaki Y, Kitamura S (2002) Epidermal growth factor inhibits the growth of TE8 esophageal cancer cells through the activation of STAT1. J Gastroenterol 37:497-503
24. Kirchhoff S, Hauser H (1999) Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis. Oncogene 18:3725-3736
25. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E (2002) IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 22:39-47
26. Kroger A, Dallugge A, Kirchhoff S, Hauser H (2003) IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo. Oncogene 22:1045-1056
27. Cuadrado A, Garcia-Fernandez LF, Gonzalez L et al (2003) Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 278:241-250
28. Mitsiades CS, Ocio EM, Pandiella A et al (2008) Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 68:5216-5225
29. Conesa A, Nueda MJ, Ferrer A, Talon M (2006) maSigPro: a method to identify significantly differential expression profiles in time-course microarray experiments. Bioinformatics 22:1096-1102
30. Kopetz VA, Penno MA, Hoffmann P, Wilson DP, Beltrame JF (2012) Potential mechanisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon - insight from a plasma proteomic approach. Int J Cardiol 156:84-91
31. Wu G, Stein L (2012) A network module-based method for identifying cancer prognostic signatures. Genome Biol 13:R112
32. Yuryev A, Mulyukov Z, Kotelnikova E et al (2006) Automatic pathway building in biological association networks. BMC Bioinformatics 7:171
33. Follis AV, Chipuk JE, Fisher JC et al (2013) PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat Chem Biol 9:163-168
34. Oh J, Kim SH, Ahn S, Lee CE (2012) Suppressors of cytokine signaling promote Fas-induced apoptosis through downregulation of NF-kappa B and mitochondrial Bfl-1 in leukemic T cells. J Immunol 189:5561-5571
35. Contri A, Brunati AM, Trentin L et al (2005) Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115:369-378
36. Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC, Lipkowitz S (1995) Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10:2367-2377
37. Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421
38. Levy DE (1995) Interferon induction of gene-expression through the Jak-Stat Pathway. Semin Virol 6:181-189
39. Fu XY, Zhang JJ (1993) Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 74:1135-1145
40. Stein S, Thomas EK, Herzog B et al (2004) NDRG1 is necessary for p53-dependent apoptosis. J Biol Chem 279:48930-48940
41. Torriglia A, Lepretre C, Padron-Barthe L, Chahory S, Martin E (2008) Molecular mechanism of L-DNase II activation and function as a molecular switch in apoptosis. Biochem Pharmacol 76:1490-1502
42. Padron-Barthe L, Courta J, Lepretre C, Nagbou A, Torriglia A (2008) Leukocyte elastase inhibitor, the precursor of L-DNase II, inhibits apoptosis by interfering with caspase-8 activation. Biochim Biophys Acta 1783:1755-1766
43. Kamath S, Buolamwini JK (2006) Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 26:569-594
44. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY (1996) Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272:719-722
45. Gilmour KC, Pine R, Reich NC (1995) Interleukin 2 activates STAT5 transcription factor (mammary gland factor) and specific gene expression in T lymphocytes. Proc Natl Acad Sci USA 92:10772-10776
46. Schere-Levy C, Buggiano V, Quaglino A et al (2003) Leukemia inhibitory factor induces apoptosis of the mammary epithelial cells and participates in mouse mammary gland involution. Exp Cell Res 282:35-47
47. Chustz RT, Nagarkar DR, Poposki JA et al (2011) Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am J Resp Cell Mol 45:145-153
48. Minamoto S, Ikegame K, Ueno K et al (1997) Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun 237:79-83
49. Wong RPC, Tsang WP, Chau PY, Co NN, Tsang TY, Kwok TT (2007) p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther 6:1054-1061
50. Yuan W, Collado-Hidalgo A, Yufit T, Taylor M, Varga J (1998) Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cell Physiol 177:174-186
51. Tseng MY, Liu SY, Chen HR et al (2009) Serine protease inhibitor (SERPIN) B1 promotes oral cancer cell motility and is over-expressed in invasive oral squamous cell carcinoma. Oral Oncol 45:771-776
52. Fombonne J, Padron L, Enjalbert A, Krantic S, Torriglia A (2006) A novel paraptosis pathway involving LEI/L-DNaseII for EGF-induced cell death in somato-lactotrope pituitary cells. Apoptosis 11:367-375
53. Papadopoulou N, Charalampopoulos I, Alevizopoulos K, Gravanis A, Stournaras C (2008) Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells. Exp Cell Res 314:3162-3174
54. Gourlay CW, Ayscough KR (2006) Actin-induced hyperactivation of the Ras signaling pathway leads to apoptosis in Saccharomyces cerevisiae. Mol Cell Biol 26:6487-6501
55. Wang C, Zhou GL, Vedantam S, Li P, Field J (2008) Mitochondrial shuttling of CAP1 promotes actin- and cofilin-dependent apoptosis. J Cell Sci 121:2913-2920
56. Giacca M (2005) HIV-1 Tat, apoptosis and the mitochondria: a tubulin link? Retrovirology 2:7
57. Utsumi T, Sakura N, Nakano K, Ishisaka R (2003) C-terminal 15 kDa fragment of cytoskeletal actin is posttranslationally N-myristoylated upon caspase-mediated cleavage and targeted to mitochondria. FEBS Lett 539:37-44
58. Parlato S, Giammarioli AM, Logozzi M et al (2000) CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J 19:5123-5134
59. Chan HL, Chou HC, Duran M et al (2010) Major role of epidermal growth factor receptor and Src kinases in promoting oxidative stress-dependent loss of adhesion and apoptosis in epithelial cells. J Biol Chem 285:4307-4318
60. Yao WJ, Gu L, Sun DG, Ka WB, Wen ZY, Chien S (2003) Wild type p53 gene causes reorganization of cytoskeleton and, therefore, the impaired deformability and difficult migration of murine erythroleukemia cells. Cell Motil Cytoskelet 56:1-12
61. Guo F, Gao Y, Wang L, Zheng Y (2003) p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities. J Biol Chem 278:14414-14419